Xenon Pharmaceuticals (XENE) Projected to Release Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.14) per share and revenue of $1.6670 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the firm earned ($0.83) EPS. On average, analysts expect Xenon Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Xenon Pharmaceuticals Trading Up 2.8%

Shares of NASDAQ XENE opened at $64.01 on Wednesday. Xenon Pharmaceuticals has a 12-month low of $32.78 and a 12-month high of $72.66. The company has a market cap of $6.19 billion, a P/E ratio of -13.62 and a beta of 0.62. The stock has a fifty day moving average price of $59.66 and a 200 day moving average price of $53.80.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. JPMorgan Chase & Co. upped their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Finally, Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $77.20.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new position in Xenon Pharmaceuticals in the fourth quarter worth about $1,125,000. Mackenzie Financial Corp acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $210,000. ADAR1 Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 7.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after acquiring an additional 14,871 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $964,000. Finally, Virtus Investment Advisers LLC lifted its stake in Xenon Pharmaceuticals by 74.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 2,568 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.